To include your compound in the COVID-19 Resource Center, submit it here.

IPI-926: Phase Ib/II data

Data from 15 evaluable patients in the Phase Ib portion of an ongoing Phase Ib/II trial showed that once-daily 110-160 mg

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE